List of Excipients in Branded Drug CHILDRENS IBUPROFEN

Generic Drugs Containing CHILDRENS IBUPROFEN

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	ibuprofen	0121-0917	ACESULFAME POTASSIUM
Pharmaceutical Associates Inc	ibuprofen	0121-0917	ANHYDROUS CITRIC ACID
Pharmaceutical Associates Inc	ibuprofen	0121-0917	GLYCERIN

What are the Most Frequently-Used Excipients in CHILDRENS IBUPROFEN?

# Of NDCs	Excipient
38	ACESULFAME POTASSIUM
10	AMMONIUM GLYCYRRHIZATE
61	ANHYDROUS CITRIC ACID

Children’s Ibuprofen Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Children’s ibuprofen is a mature OTC category with limited opportunity for API differentiation and substantial opportunity in formulation, dosing accuracy, tolerability, packaging, and channel economics. The strongest commercial position is a 100 mg/5 mL oral suspension that improves palatability, reduces dosing friction, supports preservative-conscious positioning, and complies with FDA OTC labeling requirements. The primary competitors are branded products such as Children’s Advil and Children’s Motrin, retailer private-label suspensions, chewable tablets, and combination pediatric fever products.

What is the regulatory status of children’s ibuprofen in the United States?

Children’s ibuprofen is regulated as an OTC internal analgesic, antipyretic, and fever reducer. The standard pediatric liquid concentration is 100 mg/5 mL, equivalent to 20 mg/mL. FDA labeling generally permits use in children six months and older, with weight- and age-based dosing instructions. Products should not be marketed for infants younger than six months without an appropriate regulatory basis and labeling support (U.S. Food and Drug Administration [FDA], 2023a; Electronic Code of Federal Regulations [eCFR], 2024a).

Regulatory element	Commercial implication
Active ingredient	Ibuprofen
Common liquid strength	100 mg/5 mL
Dosage form	Oral suspension or liquid
Primary uses	Fever and minor aches and pains
Pediatric population	Generally six months and older
Regulatory pathway	OTC monograph framework or approved OTC drug application, depending on product
Prescription status	Not required for compliant OTC products
Pediatric exclusivity	No current pediatric exclusivity opportunity for the established active ingredient
Biosimilar pathway	Not applicable
Orange Book status	Must be verified by exact product, NDA, and listing; private-label monograph products are generally not Orange Book drug products
Paragraph IV exposure	Usually limited for monograph-based products; relevant only where an approved NDA and listed patents are involved

The FDA’s OTC monograph system establishes permitted active ingredients, indications, labeling, and conditions of use. A manufacturer still must ensure that the finished product complies with current good manufacturing practice, stability, quality, packaging, and labeling requirements.

What excipients are used in children’s ibuprofen suspension?

The key formulation problem is that ibuprofen is poorly soluble in water. A stable pediatric product therefore requires a suspension system that maintains uniform drug distribution while allowing easy shaking and accurate dose withdrawal.

Typical excipient classes include:

Excipient function	Common options	Strategic considerations
Suspending agent	Xanthan gum, microcrystalline cellulose with carboxymethylcellulose, hypromellose, sodium carboxymethylcellulose	Controls sedimentation, redispersibility, mouthfeel, and syringe performance
Wetting agent	Polysorbate 80, poloxamer, selected surfactants	Improves API wetting but can affect taste, foam, and gastrointestinal tolerance
Sweetener	Sucrose, sorbitol, sucralose, acesulfame potassium	Determines taste, caloric content, dental positioning, and gastrointestinal profile
Flavor	Cherry, grape, berry, bubble gum, orange	Strongly affects pediatric acceptance and repeat purchase
Buffer	Citric acid, sodium citrate, phosphate systems	Controls pH, taste, preservative performance, and chemical stability
Preservative	Sodium benzoate, potassium sorbate, parabens, or preservative-free design	Influences microbiological robustness and parent acceptance
Antifoam	Simethicone or other compatible systems	May improve filling and dose measurement where foam is a manufacturing issue
Colorant	Certified synthetic colorants or color-free design	Affects visual differentiation and “clean-label” positioning
Vehicle	Purified water, glycerin, sorbitol solution, polyethylene glycol, or combinations	Controls viscosity, mouthfeel, density, and fill accuracy

The formulation should be developed around the full excipient system rather than treating each ingredient independently. A higher gum level can reduce sedimentation but produce a thick product that is difficult to draw into an oral syringe. A lower-viscosity suspension can improve dosing convenience but may require stronger shake instructions and tighter control of particle-size distribution.

What is the best excipient strategy for a new children’s ibuprofen product?

The strongest base strategy is a low- to moderate-viscosity, alcohol-free, dye-free suspension with a well-balanced sweetener and flavor system.

Suspension performance

A suspension should meet four practical requirements:

1. It should remain physically stable during ordinary storage.
2. It should redisperse rapidly with normal shaking.
3. It should deliver a consistent dose throughout the bottle.
4. It should pass through an oral syringe without excessive force.

Xanthan gum can provide strong suspension performance at relatively low concentrations, but excessive use can create stringiness and poor mouthfeel. Microcrystalline cellulose-carboxymethylcellulose systems can provide a more structured suspension with acceptable rheology, but they require careful process control during hydration and dispersion.

Particle-size reduction of ibuprofen can improve uniformity and reduce settling. It can also increase surface area, which may affect flavor perception, dissolution behavior, and physical stability. Wetting-agent selection should be evaluated with the final particle-size distribution rather than in isolation.

Taste masking

Taste is a central commercial variable. Ibuprofen has a bitter, medicinal taste that can persist after swallowing. A successful flavor system normally combines:

• Sweetness sufficient to suppress bitterness without excessive viscosity.
• A flavor profile with rapid onset and limited aftertaste.
• A buffer system that avoids sharp acidity.
• A surfactant level that does not increase bitterness or foaming.
• A mouthfeel that does not leave a chalky or greasy residue.

Berry and grape profiles are common in pediatric analgesics. A differentiated product could use a milder fruit profile, a flavor system designed for sensory neutrality, or a two-stage taste-masking approach using polymeric coating or complexation. Taste masking must not compromise suspension redispersibility or release.

Sugar-free positioning

A sugar-free product can address parents seeking lower sugar exposure and pharmacies seeking a broader product range. Sorbitol and sucralose are common tools, but sorbitol may cause gastrointestinal discomfort at sufficiently high exposure. Polyols should therefore be assessed for total daily intake at the maximum labeled dose, particularly in younger children.

A sucrose-containing product may have better taste and lower formulation complexity. Its disadvantages include higher sugar exposure, potential dental concerns, and less compatibility with “sugar-free” retail positioning. The optimal choice depends on target channel and price point.

Preservative strategy

Preservatives improve microbiological protection in multidose aqueous products. A preservative-free formulation can support a premium positioning but increases the importance of container design, microbial challenge performance, manufacturing controls, in-use stability, and package size.

A preservative-free product may be commercially attractive in single-dose or unit-dose formats. For a conventional 100 mL or 120 mL bottle, the cost and operational burden may outweigh the marketing benefit unless the product has a clear target population.

Color and allergen positioning

A dye-free suspension can appeal to parents seeking fewer unnecessary ingredients. It also reduces the risk of color variability and simplifies certain retailer claims. The main tradeoff is visual differentiation. A color-free product must use packaging, flavor, and labeling to distinguish itself on shelf.

Claims such as “gluten-free,” “dye-free,” “alcohol-free,” and “sugar-free” require documented formulation and supply-chain controls. They should not be used as substitutes for approved therapeutic claims.

What dosage forms offer the greatest commercial opportunity?

Liquid suspension remains the largest practical opportunity because it serves younger children and permits weight-based dose adjustment. Chewables and orally disintegrating formats provide secondary opportunities for older children.

Dosage form	Target user	Opportunity	Main limitation
100 mg/5 mL suspension	Children approximately six months and older	Broadest pediatric coverage and strongest pharmacy relevance	Taste, settling, preservatives, bottle handling
Unit-dose liquid sachets or cups	Travel, daycare, emergency kits	Improved convenience and reduced contamination risk	Higher packaging cost and lower volume efficiency
50 mg chewable tablets	Older children able to chew	Portable, spill-resistant, no shaking	Choking risk and limited suitability for younger children
Orally disintegrating tablet	Older children	Convenience and differentiated dosage form	Taste masking and manufacturing complexity
Powder for reconstitution	Institutional or specialty channels	Lower shipping weight and potentially longer shelf life	Reconstitution burden and dosing errors
Pediatric combination product	Fever with congestion or other symptoms	Higher basket value	Greater regulatory, safety, and dosing complexity

The most defensible initial product is a liquid suspension with an oral syringe, followed by a chewable or unit-dose extension. A combination product creates greater regulatory and safety complexity and may increase the risk of duplicate dosing when caregivers use multiple products.

How can excipients create commercial differentiation?

Excipient innovation can support commercial differentiation in five areas.

Dosing accuracy

A suspension with predictable viscosity and a calibrated oral syringe can reduce dose variability. Packaging should make the syringe easy to insert, fill, and read. A bottle adapter can reduce spills and improve dose withdrawal, but it must not obstruct cleaning or create unacceptable residual volume.

Storage and in-use stability

A formulation with strong physical and microbiological stability can support a longer shelf life and more reliable retail distribution. Stability work should address sedimentation, caking, viscosity drift, flavor loss, preservative content, microbial quality, and container closure compatibility.

Pediatric acceptability

Improved taste can increase completion of doses and repeat purchase. Commercial testing should measure not only initial preference but also aftertaste, willingness to take a second dose, and caregiver-reported resistance.

Clean-label positioning

Dye-free, sugar-free, alcohol-free, and preservative-conscious products can command a premium in selected retail channels. These claims are most effective when supported by a clear formulation rationale and packaging that communicates the benefit quickly.

Packaging and sustainability

A lighter bottle, reduced headspace, recyclable components, and lower-volume packaging can reduce shipping and material costs. The packaging must still protect against leakage, tampering, child access, and dose loss.

What patents protect children’s ibuprofen formulations?

The original composition-of-matter and basic therapeutic patent estate for ibuprofen is expired. The principal commercial barriers are therefore regulatory compliance, manufacturing capability, brand equity, retailer access, and formulation execution rather than a broad active-ingredient patent.

Potentially relevant intellectual-property categories include:

• Suspension compositions with defined rheology or particle-size distributions.
• Taste-masking systems.
• Unit-dose containers and dispensing closures.
• Orally disintegrating or chewable dosage forms.
• Manufacturing processes for micronized or coated ibuprofen.
• Packaging systems that improve dose measurement or child resistance.
• Trademarks, trade dress, and brand-specific flavor names.

Patent risk must be assessed against the exact product architecture. A generic 100 mg/5 mL suspension using conventional excipients is unlikely to face a meaningful blocking patent position solely because it contains ibuprofen. A product using a proprietary taste-masking polymer, novel delivery device, or specialized particle-engineering process could create a more material freedom-to-operate issue.

What is the Orange Book status of children’s ibuprofen?

Orange Book analysis is product-specific. A monograph-compliant private-label children’s ibuprofen product generally is not protected by an Orange Book patent listing in the same way as an approved NDA product. Branded or legacy approved products may have separate NDA records, but the presence and relevance of any listed patents must be confirmed by product name, application number, dosage form, and current listing status (FDA, 2024a).

The key distinction is:

Product type	Orange Book relevance
OTC monograph private-label suspension	Generally limited
Approved NDA pediatric ibuprofen product	Potentially relevant
Branded formulation with no active listed patent	Commercial, not necessarily patent, differentiation
Novel delivery system	Possible patent relevance
Trademarked product name	Trademark rights, not Orange Book patent protection

When does children’s ibuprofen lose exclusivity?

Ibuprofen’s core exclusivity has already expired. There is no meaningful new chemical entity exclusivity, orphan exclusivity, or biosimilar exclusivity opportunity for a conventional pediatric ibuprofen product. The market is open to multiple manufacturers that comply with FDA requirements.

A new product may still obtain limited regulatory advantages through a specific approved application, but these would not normally prevent ordinary OTC monograph competitors from selling compliant ibuprofen products. Market exclusivity is more likely to arise from retail contracts, brand loyalty, manufacturing scale, differentiated packaging, or a narrow formulation patent than from statutory exclusivity.

Are Paragraph IV challenges relevant to children’s ibuprofen?

Paragraph IV litigation is generally relevant when a generic applicant challenges an Orange Book-listed patent for an approved reference drug. It is less central for conventional OTC monograph ibuprofen products.

A Paragraph IV strategy could become relevant if a manufacturer seeks approval for a product that references an NDA with listed formulation, dosage-form, or method-of-use patents. For a standard monograph-based suspension, the more likely regulatory route is compliance with the OTC framework rather than a patent challenge against a single reference product.

What method-of-use patents apply to pediatric ibuprofen?

Broad fever and pain indications for ibuprofen are mature and generally not suitable for durable method-of-use exclusivity. Potentially narrower claims could address dosing in defined populations, administration schedules, or combination use, but their commercial value would depend on patent validity, written description, enablement, and the scope of FDA-approved labeling.

For an OTC launch, method-of-use patent protection is usually weaker than formulation and device protection because caregivers and retailers demand simple, broad labeling. A narrow patented use may not justify premium pricing unless it solves a significant dosing or adherence problem.

Does biosimilar risk affect children’s ibuprofen?

No. Ibuprofen is a small-molecule drug, not a biologic. Biosimilar competition, interchangeable biologic designation, and the Biologics Price Competition and Innovation Act do not apply. Competitive pressure comes from generic, store-brand, branded OTC, and private-label manufacturers.

Which companies compete in children’s ibuprofen?

The market includes branded consumer-health companies, generic manufacturers, contract manufacturers, and retailers.

Competitive group	Examples	Principal advantage
Branded OTC	Kenvue through Children’s Motrin; Haleon through Children’s Advil	Brand recognition and national distribution
Store brands	CVS, Walgreens, Walmart, Target, Amazon and grocery private labels	Lower price and retailer shelf access
Generic manufacturers	Perrigo and other OTC suppliers	Scale, private-label supply, and manufacturing economics
Contract manufacturers	Regional and multinational CMO suppliers	Flexible capacity and retailer-specific formulations
Specialty innovators	Smaller firms with novel devices or dosage forms	Differentiated delivery and premium positioning

Brand ownership and supply arrangements can change. Commercial diligence should distinguish label owner, manufacturer, distributor, and trademark holder.

What licensing and partnership opportunities exist?

The most realistic licensing opportunities are formulation and packaging technologies rather than ibuprofen API rights. Potential deal structures include:

1. A taste-masking license for pediatric NSAID suspensions.
2. A proprietary bottle-and-syringe dosing system.
3. A preservative-free multidose platform.
4. A unit-dose liquid package for travel and institutional use.
5. A private-label supply agreement with a national retailer.
6. A co-branding agreement with a pediatric nutrition or family-health company.
7. A contract manufacturing arrangement with a qualified OTC facility.

A formulation license should address ownership of process improvements, stability data, regulatory filings, change control, supply obligations, minimum purchase volumes, territory, and rights to future dosage forms.

What litigation and settlement issues affect the category?

A conventional children’s ibuprofen suspension has a lower patent-litigation profile than a patented extended-release, combination, or device-based product. The more significant legal risks are likely to involve:

• Product liability claims related to dosing errors.
• Alleged mislabeling or inadequate warnings.
• Child-resistant packaging failures.
• Advertising claims concerning speed, duration, or superiority.
• Trademark and trade-dress disputes.
• Contract disputes between brand owners, retailers, and manufacturers.
• Manufacturing deviations or recalls.

No product-specific litigation or settlement position should be inferred from the active ingredient alone. Any diligence report must identify the exact brand, labeler, NDA or monograph basis, manufacturer, and product configuration.

What generic launch scenarios exist for children’s ibuprofen?

Base-case launch

A manufacturer launches a 100 mg/5 mL suspension through private-label or regional pharmacy channels. Success depends on low cost, reliable supply, compliant labeling, and acceptable taste. Patent barriers are limited.

Premium formulation launch

The product uses dye-free, sugar-free, alcohol-free positioning, improved flavor, and a high-quality syringe. This supports higher gross margins but requires stronger sensory evidence and marketing discipline.

Convenience launch

Unit-dose liquid or a portable chewable format targets travel, daycare, schools, and emergency kits. Packaging costs rise, but the product can access channels where ordinary bottles are inconvenient.

Device-led launch

A dosing closure or integrated syringe improves accuracy and reduces spills. The device can create a stronger patent and trade-dress position than the suspension alone.

How strong is the patent estate for children’s ibuprofen?

The patent estate for conventional children’s ibuprofen is weak as a blocking platform and stronger as a selective differentiation tool.

Asset category	Relative strength
Ibuprofen active ingredient	Very low; long-expired core protection
Standard 100 mg/5 mL suspension	Low to moderate, depending on claims
Taste-masking technology	Moderate if technically narrow and well supported
Novel dispensing device	Moderate to strong if non-obvious and commercially adopted
Packaging configuration	Moderate, often supported by design and trademark rights
Pediatric method of use	Generally low for broad indications
Brand and trade dress	Potentially strong commercially, but separate from patent exclusivity
Manufacturing process	Moderate if difficult to design around and supported by process know-how

What revenue exposure does children’s ibuprofen create?

Product-specific revenue is generally not disclosed separately by large consumer-health companies. Exposure is best evaluated through category share, retail distribution, seasonality, and gross margin rather than reported brand revenue.

The category has several commercial characteristics:

• Demand rises during respiratory-virus and school seasons.
• Retailer private labels place sustained pressure on price.
• Liquid products typically offer greater formulation differentiation than basic tablets.
• Stockouts can shift consumers between branded and private-label products quickly.
• Packaging and flavor improvements can support premium pricing but do not eliminate substitution risk.
• Retailer relationships may be more valuable than patent exclusivity.

A differentiated product should target a specific economic outcome, such as lower cost per shipped dose, reduced returns from leakage, higher repeat purchase, or improved retailer margin.

Key Takeaways

• Children’s ibuprofen is a mature OTC market with expired core API exclusivity.
• The standard commercial platform is a 100 mg/5 mL oral suspension.
• The most valuable excipient work concerns suspension stability, taste masking, viscosity, preservative strategy, and dose delivery.
• Dye-free, sugar-free, alcohol-free, and preservative-conscious positioning can support premium segmentation.
• Patent opportunities are concentrated in formulation, taste masking, manufacturing, and dispensing devices.
• Paragraph IV litigation and biosimilar competition are generally limited for conventional monograph products.
• The strongest launch paths are private label, premium pediatric suspension, unit-dose convenience, and device-led dosing.
• Regulatory, manufacturing, packaging, and retailer access are more important barriers than the expired ibuprofen patent estate.

FAQs

Can children’s ibuprofen be formulated without a preservative?

Yes. A preservative-free product is possible, but it requires stronger control of microbial contamination, container closure performance, in-use stability, and manufacturing hygiene.

Is a sugar-free children’s ibuprofen product commercially attractive?

Yes. Sugar-free positioning can appeal to parents and retailers, but sweetener selection must control bitterness without creating excessive gastrointestinal exposure from polyols such as sorbitol.

Can a manufacturer patent a new children’s ibuprofen flavor?

A flavor alone may not provide meaningful patent protection. A patent position is stronger when the flavor is part of a technically supported taste-masking composition or dosage-form system with defined performance characteristics.

What is the most defensible premium claim for a new pediatric ibuprofen product?

Dosing convenience supported by an accurate oral syringe and a well-designed bottle adapter is generally more defensible than broad claims of faster action or superior fever reduction.

Is ibuprofen suitable for an infant product below six months of age?

Conventional OTC pediatric labeling generally does not support use below six months. Any product targeting younger infants would require a separate regulatory and clinical assessment rather than a routine extension of the standard children’s ibuprofen label.

References

1. Electronic Code of Federal Regulations. (2024a). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343

2. U.S. Food and Drug Administration. (2023a). Drug facts label: Children’s ibuprofen oral suspension, 100 mg/5 mL. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2024b). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-drugs

5. United States Pharmacopeia. (2024). General chapter <795>: Pharmaceutical compounding - nonsterile preparations. United States Pharmacopeial Convention.